If Haemonetics was on your watchlist rather than in your portfolio, the move over this stretch may feel like a missed shot. For Haemonetics shareholders, the return from the start of the year was 48.2%, including dividends. That gain arrived while analysts disagreed sharply on whether plasma growth and hospital technology could really compound, or whether regulation and competition would cap the upside. Which of those business assumptions looked better supported back on 1 January 2026?
Haemonetics has already moved. Pinpoint other ways to investigate the theme among 34 healthcare AI stocks.
The Two Haemonetics Stories Investors Had To Weigh
The shares cost US$80.15 at the start of the period, and Haemonetics sat between two sharply different narratives about where its blood management franchise could go next.
The bullish camp saw a Fair Value of US$108, a price that reflected expectations for technology driven recurring revenue, including share gains in plasma software and a hospital segment that could grow into a higher margin, larger slice of group sales.
The cautious view pointed to a Fair Value of US$65.5, tied to worries that regulatory pressure, reimbursement changes, and advances in bloodless surgery might restrict plasma growth and keep earnings expansion more muted.
What The Results Changed For The Haemonetics Debate
Haemonetics landing a full NexSys PCS rollout with CSL Plasma and securing FDA approval for the PerQseal Elite system backed the optimistic case that plasma technology and hospital devices could support higher quality revenue. The counterpoint sat in the numbers. Q1 2027 revenue reached US$339.4 million, yet net income slipped to US$33.01 million and net margin moved from 10.6% to 9.7%, so the evidence cut both ways.
The key assumption was not just growth but profitable growth. When you look at another medical device stock, check whether rising sales are matched by stable or improving net margin so the thesis relies on more than volume alone.
What Haemonetics' Run Up 48% Already Assumes
Haemonetics now trades at US$119 after a 48.2% gain from the start of the year, while the selected Narrative’s Fair Value sits below the current price.
The Narrative leans on contract terms and cost pressures rather than questioning demand. For today’s price to add up, a buyer would need confidence that higher input costs and contract concessions do not eat into margins and free cash flow over time.
"The numbers imply the share price already embeds a continuation of recent revenue growth, margin expansion and cash generation, leaving limited room for disappointment if cost pressures or competitive responses intensify. Although Haemonetics is capturing strong plasma volume and disposables growth in North America and EMEA, sustained external cost pressures from tariffs, higher oil and transportation costs, material inflation and elevated medical plan claims could erode the margin benefits of this higher throughput and cap the contribution to net margins and earnings."
One Narrative disagrees with today's price. → See where this Narrative says Haemonetics should trade
Looking One Step Beyond Haemonetics
Haemonetics lives in blood management. Your next question could be broader patient care.
Hospitals that buy plasma systems also depend on reliable testing and monitoring.
They need diagnostics that catch disease early and track ongoing treatment.
Another large healthcare group focuses there, building lab tools and point of care checks.
Its products do not rely on Haemonetics, yet they tap the same budgets and could gain importance if demand for better testing keeps rising.
One Narrative has already put a figure on it. → Uncover the company trading 14% below one Narrative's Fair Value
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com